SSA
LCTX icon

Schonfeld Strategic Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.9K Buy
48,017
+34,699
+261% +$58.5K ﹤0.01% 1922
2025
Q4 		$22.2K Buy
+13,318
New +$23.1K ﹤0.01% 1923
2025
Q3 		– Sell
-16,126
Closed -$14.6K – 2411
2025
Q2 		$14.6K Buy
+16,126
New +$9.57K ﹤0.01% 1947
2023
Q2 		– Sell
-22,300
Closed -$33.5K – 2343
2023
Q1 		$33.5K Buy
+22,300
New +$31.1K ﹤0.01% 1803
2021
Q2 		– Sell
-33,574
Closed -$78K – 2133
2021
Q1 		$78K Buy
33,574
+15,841
+89% +$38K ﹤0.01% 1692
2020
Q4 		$32K Buy
+17,733
New +$24.8K ﹤0.01% 1515

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return